United States · Platforms & data · Yahoo Finance

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

Published by Yahoo Finance · United States 12 h ago

Krystal Biotech (KRYS) just paired a third quarter earnings beat with a new US$400 million share repurchase plan, giving investors fresh numbers on Vyjuvek demand and updated…

Read the full article on Yahoo Finance Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (finance.yahoo.com)

Also worth reading

The Motley Fool

Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?

Share

Also worth reading

Fabrinet (FN) Q1 2027 Earnings Call Transcript

Angel Oak Financial Strategies Income Term declares $0.115 dividend

Adani Group seeks $1.5 bln loan for data center expansion- Economic Times

Stock market after midterm elections: What S&P 500 history shows

Amundi Funds - Income Opportunities A70 SGD MTD2 D

S&P 500, Nasdaq Drop As Capex Concerns Grip Tech Investors, Outweighing US-Iran Diplomacy Hope — ORCL, META, PLTR, AAPL In Focus